Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496126 | 1.00 | RECQL (0.44) | RECQLDRD2DRD4DRD3HRH3 | |
| SCHEMBL3497993 | 0.87 | HRH3 (0.39) | DRD2DRD4DRD3HRH3ALDH1A1 | |
| SCHEMBL3498749 | 0.87 | BRD4 (0.39) | DRD2DRD4DRD3HRH3ALDH1A1 | |
| SCHEMBL3496267 | 0.87 | BRD4 (0.39) | DRD2DRD4DRD3HRH3ALDH1A1 | |
| SCHEMBL3498759 | 0.87 | HRH3 (0.39) | DRD2DRD4DRD3HRH3ALDH1A1 | |
| SCHEMBL3497148 | 0.83 | DRD2 (0.57) | RECQLDRD2DRD4DRD3HRH3 | |
| SCHEMBL3496672 | 0.80 | CYP11B1 (0.47) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL3497795 | 0.80 | CYP11B1 (0.47) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL3495753 | 0.80 | CYP11B1 (0.47) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL3496759 | 0.79 | TP53 (0.51) | DRD2DRD4DRD3HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | claimed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | claimed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | RECQL 2351/4885DRD2 419/4885DRD4 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.